| Single-cell and spatial omics techniques |
Detailed mapping of tumor heterogeneity; identification of rare subpopulations (e.g., cancer stem cells and resistant clones) |
Tailoring nanotherapeutics to target elusive, drug-resistant niches and specific cellular subpopulations |
| Integrative analysis of genomics, transcriptomics, proteomics, metabolomics, and epitranscriptomics |
Comprehensive molecular portraits; uncovering complex networks, regulatory nodes, and feedback loops |
Designing nanocarriers that precisely target key signaling pathways and regulatory hubs driving tumor progression and resistance |
| Machine learning and artificial intelligence algorithms |
Identification of novel biomarkers; prediction of functional consequences of mutations |
Guiding the customization of smart, adaptive nanoparticles that adjust drug release profiles based on the tumor's evolving molecular landscape |
| Integration of omics data with imaging agents and biosensors embedded in nanocarriers |
Real-time monitoring of treatment efficacy and tumor molecular responses |
Enabling theranostic platforms that provide dynamic feedback to adjust treatment regimens in real time, ensuring sustained therapeutic effectiveness |
| Correlating multi-omics signatures with drug response profiles |
Patient stratification; identification of individualized biomarkers |
Functionalizing nanocarriers with specific ligands to achieve highly personalized therapy tailored to each patient's unique molecular profile |
